How effective is your Stem Cell Therapy for a Traumatic Brain Injury?
Stem cell therapy for traumatic brain injury (TBI) has shown encouraging evidence of effectiveness.

The strongest data come from the STEMTRA trial, a randomized, sham-controlled study published in Neurology, in which people with chronic TBI who received surgically implanted, modified bone-marrow-derived mesenchymal stromal cells (MSCs) had significantly greater improvement in motor function than those who had sham surgery; in the interim analysis, roughly 39% of treated patients reached a clinically meaningful motor improvement, compared with about 7% in the control group. Based on these results, regulators in Japan granted that specific product conditional, time-limited approval in 2024. Studies using other cell types and routes, including intravenous (IV) delivery, report acceptable safety and improvement in some patients. At Stem Cell Mexico, TBI protocols use only allogeneic MSCs from Wharton's jelly, usually by IV infusion, as a supportive treatment whose results vary between individuals. We do not report satisfaction rates or success percentages without published data to support them.
This guide explains what "effective" means in TBI, what the studies show, which factors influence results and how progress should be measured.
Why TBI is difficult to treat
The brain has limited capacity to replace neurons lost after injury. After the initial trauma, a secondary injury process unfolds over days, weeks and even years: chronic inflammation, damage to the connections between neurons (white matter), changes in blood flow and the formation of scar tissue. Many people with chronic TBI also have persistent activation of the brain's immune cells, which may contribute to fatigue, cognitive slowing and mood changes. Effective treatments must therefore work on several fronts: protecting remaining neurons, reducing harmful inflammation, supporting new connections and helping the brain relearn skills through practice. This complexity explains why no single treatment, including cell therapy, works for everyone, and why combining approaches is often necessary.
What "effective" means after a brain injury
In TBI, effectiveness is not a single yes-or-no answer. Meaningful outcomes can include:
- Motor function: strength, coordination, walking, hand use.
- Cognition: attention, memory, processing speed, executive function.
- Communication: speech clarity, word finding.
- Daily function and independence: self-care, mobility, work or school participation.
- Symptoms: headaches, fatigue, sleep, mood.
- Participation in rehabilitation: energy and engagement in therapy.
Studies usually measure one or two of these with standardized scales. Improvement in one area does not guarantee improvement in others.
What the evidence shows
STEMTRA: the most rigorous trial to date
- Population: about 60 adults with chronic motor deficits at least one year after TBI.
- Treatment: SB623, a modified bone-marrow-derived MSC product, implanted stereotactically (through small openings in the skull) around the injured brain area, compared with a sham surgery.
- Main result: greater improvement in motor function on the Fugl-Meyer motor scale at 24 weeks in the cell group; about 39% of treated patients achieved a clinically meaningful improvement versus about 7% of controls in the interim analysis.
- Later reports: longer follow-up and analyses, including a 2024 publication in Neurology, have continued to examine the durability of the effect and which patients respond best.
- Regulatory milestone: in 2024, Japan granted conditional, time-limited approval for this product for chronic motor paralysis after TBI.
Important: these results apply to a specific product delivered by neurosurgery. They do not automatically apply to IV umbilical cord MSCs.
Other clinical studies
Reviews of clinical trials in TBI describe studies using bone marrow cells, umbilical cord cells and other products, delivered intravenously, intrathecally or directly. They generally report acceptable safety and improvements in neurological or functional scores in some patients.
Safety context
Large safety analyses of IV MSCs show temporary fever as the most consistent side effect, without increased infection, thrombosis, cancer or death in controlled trials, which supports continued research into less invasive routes.
What effectiveness means for IV Wharton's jelly MSCs
IV MSCs are thought to act by reducing chronic neuroinflammation, modulating the immune system and releasing neurotrophic signals that may support neuroplasticity. Some patients report improvements in energy, fatigue, focus, mood or motor control, sometimes noticed first by family members or therapists. A realistic expectation is that results vary: some patients improve meaningfully, others more modestly.
Understanding placebo and natural recovery
Measuring effectiveness in TBI is challenging because recovery can continue slowly over years, symptoms fluctuate with sleep, stress and activity, and expectations influence how people feel. In uncontrolled studies, it is difficult to know how much improvement is due to treatment, natural recovery, rehabilitation or the placebo effect. STEMTRA addressed this with a sham surgery control group, which is why its results carry more weight. For individual patients, recording a stable baseline before treatment and using the same objective measures afterward is the best way to interpret change honestly.
Factors that influence results
- Severity and location of the injury: focal and diffuse injuries respond differently.
- Time since injury: the brain is more plastic early, but improvement can occur years later.
- Age and general health: cardiovascular health, diabetes, sleep and nutrition matter.
- Rehabilitation intensity: improvements are most likely when treatment is combined with active, goal-directed therapy.
- Mood and motivation: depression and apathy are common after TBI and influence participation.
- Medications: some sedating or anti-seizure drugs can affect alertness and engagement.
- Cell product, dose and route.
What patients and families commonly report
When improvements occur after regenerative treatment for TBI, families often describe them in practical terms: more energy during the day, longer participation in therapy sessions, slightly better balance or hand control, clearer speech, improved mood or more initiative. These changes are usually gradual and may only become clear over several weeks or months. Because they are subjective, it is important to confirm them with the objective measures described below and to discuss them with your rehabilitation team.
How progress should be measured
To know whether treatment helped, measure before and after using:
- Standardized motor scales such as Fugl-Meyer, timed walking tests and grip strength.
- Cognitive screening or neuropsychological testing when appropriate.
- Functional measures such as independence in daily activities.
- Patient and caregiver questionnaires on fatigue, mood and quality of life.
- Videos and therapist reports.
Evaluations at three and six months, and later, help separate treatment effects from natural day-to-day variation. Sharing these results with your neurologist and therapists allows everyone involved in your care to make decisions based on the same information.
When to adjust expectations
Regenerative treatment is unlikely to restore functions lost to severe, extensive tissue destruction, and it cannot replace rehabilitation, medications for seizures or mood, or assistive technology. If improvement does not occur after an adequate period, it is important to review goals with your neurologist and rehabilitation team rather than pursuing repeated treatments without measured benefit.
Can treatment be repeated?
Some patients consider additional sessions if they notice improvement. Decisions about repeat treatment should be based on documented changes over several months, not on a fixed schedule or package. If there is no measurable benefit after an adequate period, repeating the same treatment is unlikely to be helpful.
The role of rehabilitation
The U.S. National Institute of Neurological Disorders and Stroke (NINDS) emphasizes that rehabilitation is the foundation of TBI recovery. Regenerative therapy may help create a better environment for repair, but rehabilitation is what translates that environment into function. Patients who continue intensive, goal-directed therapy after treatment give themselves the best chance of benefit.
Regulatory context
The FDA has not approved stem cell products for TBI. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS.
Who may be a candidate
- Medically stable after TBI, with controlled seizures if present.
- Specific, measurable goals and access to rehabilitation.
- No active infection and no cancer within the past five years.
- Realistic expectations about gradual, partial improvement.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
- An additional intrathecal application (similar to an epidural, usually about 60 million cells) for some neurological conditions, only after the doctor reviews your medical reports and confirms you are a candidate.
- One night at our facilities, sometimes two, with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask during your evaluation
- What evidence supports this approach for my type of injury?
- What results are realistic for me, and how will we measure them?
- How does this differ from the surgical approach studied in STEMTRA?
- How should I adjust my rehabilitation after treatment?
- When should we decide whether it worked?
Bottom line
Evidence for stem cell therapy in TBI is encouraging, especially from the STEMTRA trial of a surgically implanted MSC product, and results with IV Wharton's jelly MSCs vary between individuals. Treatment works best as a supportive complement to rehabilitation, with goals measured objectively. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your injury, goals and medical history.
References
- Kawabori M et al. Mesenchymal stromal cell implants for chronic motor deficits after traumatic brain injury (STEMTRA trial). Neurology, 2024 (opens in a new tab)
- Kawabori M et al. Cell therapy for chronic TBI: interim analysis of the randomized controlled STEMTRA trial. Neurology, 2021 (opens in a new tab)
- National Institute of Neurological Disorders and Stroke (NINDS, NIH): Traumatic brain injury (opens in a new tab)
- Traumatic brain injury and stem cells: an overview of clinical trials, the current treatments and future therapeutic approaches (review, PMC) (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
